Literature DB >> 19637086

Maintenance therapy for central nervous system lymphoma with rituximab.

Douglas E Ney, Lauren E Abrey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19637086     DOI: 10.1080/10428190903128645

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  8 in total

1.  Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma.

Authors:  Prakash Ambady; Rongwei Fu; Laszlo Szidonya; David M Peereboom; Nancy D Doolittle; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2020-02-05       Impact factor: 4.130

2.  Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.

Authors:  Leslie L Muldoon; Seth J Lewin; Edit Dósa; Dale F Kraemer; Michael A Pagel; Nancy D Doolittle; Edward A Neuwelt
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

Review 3.  Management of elderly patients with primary central nervous system lymphoma.

Authors:  Mariza Daras; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

4.  Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.

Authors:  Prakash Ambady; Rongwei Fu; Joao Prola Netto; Cymon Kersch; Jenny Firkins; Nancy D Doolittle; Edward A Neuwelt
Journal:  Fluids Barriers CNS       Date:  2017-06-02

5.  Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort.

Authors:  Christian Iorio-Morin; Gérald Gahide; Christophe Morin; Davy Vanderweyen; Marie-André Roy; Isabelle St-Pierre; Karine Massicotte-Tisluck; David Fortin
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

6.  Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies.

Authors:  Lauren R Schaff; Prakash Ambady; Nancy D Doolittle; Christian Grommes
Journal:  Ann Lymphoma       Date:  2021-03

7.  Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma.

Authors:  Lisa Modelevsky; Richard Tizon; Samantha N Reiss; Marcel Smith; Rachel Garonce; Thomas Kaley
Journal:  CNS Oncol       Date:  2018-09-17

8.  Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review.

Authors:  Mazie Tsang; James L Rubenstein; Elisa Jacobsen Pulczynski
Journal:  Ann Lymphoma       Date:  2021-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.